Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study-Reference-Cited by-同舟云学术

Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study

Published:2022-04-20 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Mehta Kapil D,Sharma Jai B,Anand Ashok,Reddy N Pavan K,Kadam Pramod,Debnath Khokan,Bhapkar Sandeep,Thampi Bini M

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference28 articles.

1. Management of acute bacterial skin and skin structure infections in India: are we equipped to meet the challenges of the growing menace of methicillin-resistant Staphylococcus aureus?;Mahakalkar C;Int Surg J,2020

2. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs;Falcone M;Intern Emerg Med,2016

3. Acute bacterial skin and skin structure infections. developing drugs for treatment. Guidance for industry. (2013). Accessed: March 15, 2019: https://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf.

4. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update;Esposito S;J Chemother,2017

5. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital;Pollack CV Jr;J Emerg Med,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral);Indian Journal of Medical Microbiology;2024-01

2. Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?;Pharmaceutics;2023-03-01